In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Supernus Pharmaceuticals (SUPN – Research Report), with a price target of $43.00. The company’s shares closed yesterday at $32.91.
Amsellem covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Alkermes, and Revance Therapeutics. According to TipRanks, Amsellem has an average return of -2.4% and a 41.85% success rate on recommended stocks.
Supernus Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $43.00.
See the top stocks recommended by analysts >>
SUPN market cap is currently $1.79B and has a P/E ratio of 37.81.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
Read More on SUPN:
